Flublok Recipients vs SD-IIV Recipients: Number of Adults 18-49 Years Old Hospitalized With PCR-confirmed Influenza
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.000136 | 0.000102 | 0.00018 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.000146 | 0.000119 | 0.00018 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0000105 | -0.0000581 | 0.0000416 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.928 | 0.653 | 1.32 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.928 | 0.653 | 1.32 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Flublok Recipients than on SD-IIV Recipients | 94,900 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Flublok Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive Flublok Quadrivalent vaccine.~Flublok Quadrivalent: Flublok Quadrivalent vaccine is a recombinant hemagglutinin influenza vaccine indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine for adults 18 years of age and older. Use of recombinant DNA techniques to produce vaccine antigen expressed in cell culture is a method that avoids growing the influenza viruses in embryonated hen's eggs. | 48 | 353,562 | OG000 | ClinicalTrials.gov |
| Group 2 | SD-IIV Recipients | Kaiser Permanente Northern California members aged 18-64 years who receive standard dose inactivated influenza vaccine (SD-IIV).~Standard Dose Inactivated Influenza Vaccine (SD-IIV): For the 2018-2019, 2019-2020, and 2020-2021 flu seasons, the primary SD-IIVs used will be Fluarix Quadrivalent and Flulaval Quadrivalent. | 88 | 601,514 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | OTHER_PRE_SPECIFIED | ClinicalTrials.gov |
| Title | Number of Adults 18-49 Years Old Hospitalized With PCR-confirmed Influenza | ClinicalTrials.gov |
| Description | Patients who receive either Flublok or SD-IIV will be retroactively assessed for whether they had an inpatient stay and had a PCR-confirmed positive influenza test (≥14 days after vaccination) as recorded in their electronic medical record by the end of the influenza season (April 30). | ClinicalTrials.gov |
| Time frame | Up to 8 months | ClinicalTrials.gov |
| Population | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years | ClinicalTrials.gov |
| NCT number | NCT03694392 | ClinicalTrials.gov |
| Phases | ClinicalTrials.gov | |
| Conditions | Influenza, Pneumonia, Lower Respiratory Tract Infection, Acute Myocardial Infarction, Congestive Heart Failure, Stroke | ClinicalTrials.gov |
| Interventions | Flublok Quadrivalent, Standard Dose Inactivated Influenza Vaccine (SD-IIV) | ClinicalTrials.gov |
| Lead sponsor | Kaiser Permanente | ClinicalTrials.gov |
| Results first posted | 2025-04-08 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT03694392?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.